Hematopoietic stem cells for cancer immunotherapy.

Area of Science:

• Immunology
• Oncology
• Stem Cell Biology

Background:

• Hematopoietic stem cells (HSCs) are a potential target for cancer immunotherapy.
• Engineering HSCs with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) can direct immune responses against tumor-associated antigens.

Purpose of the Study:

• To review the potential of TCR- or CAR-engineered HSCs for cancer and leukemia immunotherapy.
• To discuss the advantages of using HSCs for generating continuous anti-cancer effector cells.

Main Methods:

• Review of experimental and preclinical studies on TCR- and CAR-engineered HSCs.
• Discussion of in vivo T cell production and CAR-engineered myeloid/NK cell generation.

Main Results:

• Engineered HSCs can provide a sustained source of anti-tumor T cells, potentially overcoming T cell anergy and exhaustion.
• In vivo T cell production from HSCs ensures allelic exclusion, preventing unwanted TCR mis-pairing.
• CAR-engineered HSCs can generate diverse effector cells (T, myeloid, NK) for broader anti-tumor activity.

Conclusions:

• TCR- and CAR-engineered HSCs represent a viable strategy for sustained cancer immunotherapy.
• This approach may be integrated into autologous HSC transplant protocols to enhance graft-versus-tumor effects.